This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Explore a selection of our essential drug information below, or:
Identification
- Generic Name
- Aloxiprin
- DrugBank Accession Number
- DB13509
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental
- Structure
Structure for Aloxiprin (DB13509)
- Weight
- Average: 282.119
Monoisotopic: 281.9900796 - Chemical Formula
- C9H8Al2O7
- Synonyms
- Aloxiprin
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbciximab The risk or severity of bleeding can be increased when Aloxiprin is combined with Abciximab. Acarbose Aloxiprin may increase the hypoglycemic activities of Acarbose. Aceclofenac The therapeutic efficacy of Aloxiprin can be decreased when used in combination with Aceclofenac. Acenocoumarol Aloxiprin may increase the anticoagulant activities of Acenocoumarol. Acetaminophen The risk or severity of adverse effects can be increased when Acetaminophen is combined with Aloxiprin. - Food Interactions
- Not Available
Categories
- ATC Codes
- N02BA02 — Aloxiprin
- N02BA — Salicylic acid and derivatives
- N02B — OTHER ANALGESICS AND ANTIPYRETICS
- N02 — ANALGESICS
- N — NERVOUS SYSTEM
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as acylsalicylic acids. These are o-acylated derivatives of salicylic acid.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Benzene and substituted derivatives
- Sub Class
- Benzoic acids and derivatives
- Direct Parent
- Acylsalicylic acids
- Alternative Parents
- Phenol esters / Benzoic acids / Phenoxy compounds / Benzoyl derivatives / Dicarboxylic acids and derivatives / Carboxylic acid esters / Carboxylic acids / Organic oxides / Organic aluminium salts / Hydrocarbon derivatives show 1 more
- Substituents
- Acylsalicylic acid / Aromatic homomonocyclic compound / Benzoic acid / Benzoyl / Carbonyl group / Carboxylic acid / Carboxylic acid derivative / Carboxylic acid ester / Dicarboxylic acid or derivatives / Hydrocarbon derivative show 7 more
- Molecular Framework
- Aromatic homomonocyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 6QT214X4XU
- CAS number
- 9014-67-9
- InChI Key
- MXCPYJZDGPQDRA-UHFFFAOYSA-N
- InChI
- InChI=1S/C9H8O4.2Al.3O/c1-6(10)13-8-5-3-2-4-7(8)9(11)12;;;;;/h2-5H,1H3,(H,11,12);;;;;/q;2*+3;3*-2
- IUPAC Name
- dialuminium(3+) ion 2-(acetyloxy)benzoic acid trioxidandiide
- SMILES
- [O--].[O--].[O--].[Al+3].[Al+3].CC(=O)OC1=CC=CC=C1C(O)=O
References
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 36.2 mg/mL ALOGPS logP 1.19 ALOGPS logP 1.24 Chemaxon logS -0.76 ALOGPS pKa (Strongest Acidic) 3.41 Chemaxon pKa (Strongest Basic) -7.1 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 3 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 63.6 Å2 Chemaxon Rotatable Bond Count 3 Chemaxon Refractivity 44.45 m3·mol-1 Chemaxon Polarizability 16.96 Å3 Chemaxon Number of Rings 1 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS splash10-0fep-5940000000-9a62351b690c0b959c90 - Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Drug created at June 23, 2017 20:43 / Updated at February 21, 2021 18:54